The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease in mainland China

Clinica Chimica Acta

Volumn 411, Issue 19-20, 2010, Pages 1461-1465

  Zhou, Feng ^a   Xia, Bing ^a   Wang, Fubing ^a   Shrestha, Umid Kumar ^a   Chen, Min ^a   Wang, Honglin ^a   Shi, Xianyan ^a   Chen, Zhitao ^a   Li, Jin ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

ASCA; Crohn's disease; PANCA; Phenotype; Ulcerative colitis

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; SACCHAROMYCES CEREVISIAE ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CHILD; CHINA; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENTERITIS; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, FUNGAL; CASE-CONTROL STUDIES; CHINA; COLITIS, ULCERATIVE; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; HUMANS; INFLAMMATORY BOWEL DISEASES; PREVALENCE; SACCHAROMYCES CEREVISIAE;

SACCHAROMYCES CEREVISIAE;

EID: 77955055367     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.05.041     Document Type: Article

References (38)

1. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 2002, 347:417-429.
2. Amre D.K., Lu S.E., Costea F., Seidman E.G. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol 2006, 101:645-652.
3. Nielsen O.H., Vainer B., Madsen S.M., Seidelin J.B., Heegaard N.H. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol 2000, 95:359-367.
4. Klebl F.H., Bataille F., Bertea C.R., Herfarth H., Hofstädter F., Schölmerich J., et al. Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease. Inflamm Bowel Dis 2003, 9:302-307.
5. Koutroubakis I.E., Petinaki E., Mouzas I.A., Vlachonikolis I.G., Anagnostopoulou E., Castanas E., et al. Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol 2001, 96:449-454.
6. Reese G.E., Constantinides V.A., Simillis C., Darzi A.W., Orchard T.R., Fazio V.W., et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 2006, 101:2410-2422.
7. Vasiliauskas E.A., Plevy S.E., Landers C.J., Binder S.W., Ferguson D.M., Yang H., et al. Perinuclear anti-neutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 1996, 110:1810-1819.
8. Spivak J., Landers C.J., Vasiliauskas E.A., Abreu M.T., Dubinsky M.C., Papadakis K.A., et al. Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease. Inflamm Bowel Dis 2006, 12:1122-1130.
9. Bernstein C.N., Orr K., Blanchard J.F., Sargent M., Workman D. Development of an assay for antibodies to Saccharomyces cerevisiae: Easy, cheap and specific for Crohn's disease. Can J Gastroenterol 2001, 15:499-504.
10. Sutton C.L., Yang H., Li Z., Rotter J.I., Targan S.R., Braun J. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut 2000, 46:58-63.
11. Lawrance I.C., Murray K., Hall A., Sung J.J., Leong R. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients. Am J Gastroenterol 2004, 99:2186-2194.
12. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989, 24:2-6. (suppl).
13. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955, 29:1041-1048.
14. Best W.R., Becktel J.M., Singleton J.W., Kern F. Development of a Crohn's disease activity index. Gastroenterology 1976, 70:439-444.
15. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(Suppl A):5-36.
16. Geboes K., De Hertogh G. Indeterminate colitis. Inflamm Bowel Dis 2003, 9:324-331.
17. Dubinsky M.C., Ofman J.J., Urman M., Targan S.R., Seidman E.G. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2001, 96:758-765.
18. Kim B.G., Kim Y.S., Kim J.S., Jung H.C., Song I.S. Diagnostic role of anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic antibodies in patients with inflammatory bowel disease. Dis Colon Rectum 2002, 45:1062-1069.
19. Elitsur Y., Lawrence Z., Tolaymat N. The diagnostic accuracy of serologic markers in children with IBD: the West Virginia experience. J Clin Gastroenterol 2005, 39:670-673.
20. Saibeni S., Folli C., de Franchis R., Borsi G., Vecchi M. Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases. Dig Liver Dis 2003, 35:862-868.
21. Cho J.H., Weaver C.T. The genetics of inflammatory bowel disease. Gastroenterology 2007, 133:1327-1339.
22. Anand V., Russell A.S., Tsuyuki R., Fedorak R. Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn's disease and ulcerative colitis. Can J Gastroenterol 2008, 22:33-36.
23. Sugi K., Saitoh O., Matsuse R., Tabata K., Uchida K., Kojima K., et al. Antineutrophil cytoplasmic antibodies in Japanese patients with inflammatory bowel disease: prevalence and recognition of putative antigens. Am J Gastroenterol 1999, 94:1304-1312.
24. Riis L., Vind I., Vermeire S., Wolters F., Katsanos K., Politi P., et al. The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Inflamm Bowel Dis 2007, 13:24-32.
25. Damoiseaux J.G., Bouten B., Linders A.M., Austen J., Roozendaal C., Russeli M.G., et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: high prevalence in patients with celiac disease. J Clin Immunol 2002, 22:281-288.
26. Mokrowiecka A., Gasiorowska A., Malecka-Panas E. pANCA and ASCA in the diagnosis of different subtypes of inflammatory bowel disease. Hepatogastroenterology 2007, 54:1443-1448.
27. Arnott I.D., Landers C.J., Nimmo E.J., Drummond H.E., Smith B.K., Targan S.R., et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol 2004, 99:2376-2384.
28. Zholudev A., Zurakowski D., Young W., Leichtner A., Bousvaros A. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004, 99:2235-2241.
29. Peeters M., Joossens S., Vermeire S., Vlietinck R., Bossuyt X., Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001, 96:730-734.
30. Quinton J.F., Sendid B., Reumaux D., Duthilleul P., Cortot A., Grandbastien B., et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998, 42:788-791.
31. Seibold F., Stich O., Hufnagl R., Kamil S., Scheurlen M. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study. Scand J Gastroenterol 2001, 36:196-201.
32. Buhner S., Buning C., Genschel J., Kling K., Herrmann D., Dignass A., et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation?. Gut 2006, 55:342-347.
33. Sandborn W.J., Loftus E.V., Colombel J.F., Fleming K.A., Seibold F., Homburger H.A., et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2001, 7:192-201.
34. Israeli E., Grotto I., Gilburd B., Balicer R.D., Goldin E., Wiik A., et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005, 54:1232-1236.
35. Mainardi E., Villanacci V., Bassotti G., Liserre B., Rossi E., Incardona P., et al. Diagnostic value of serological assays in pediatric inflammatory bowel disorders. Digestion 2007, 75:210-214.
36. Jiang L., Xia B., Li J., Ye M., Yan W., Deng C., et al. Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China. Inflamm Bowel Dis 2006, 12:212-217.
37. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem 2006, 52:171-181.
38. Irwig L., Tosteson A.N., Gatsonis C., Lau J., Colditz G., Chalmers T.C., et al. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med 1994, 120:667-676.